Literature DB >> 5585236

On the development of alloxan diabetes in mice.

I Lundquist, C Rerup.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5585236     DOI: 10.1016/0014-2999(67)90020-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  7 in total

1.  Antidiabetogenic action of truncated glucagon-like peptide-1 in mice.

Authors:  B Ahrén
Journal:  Endocrine       Date:  1995-05       Impact factor: 3.633

2.  Serum mineral changes in alloxan diabetes before and after treatment with some hypoglycemic drugs.

Authors:  D Halim; K Khalifa; R Awadalah; E A El-Dessoukey; T Hafez; Z El-Hawary
Journal:  Z Ernahrungswiss       Date:  1977-03

3.  Diabetogenic action of streptozotocin: relationship of dose to metabolic response.

Authors:  A Junod; A E Lambert; W Stauffacher; A E Renold
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

4.  Serum enzyme changes due to trace amounts of some transition metal ions on the induction of experimental diabetes.

Authors:  R Awadallah; A Hanna
Journal:  Z Ernahrungswiss       Date:  1980-06

5.  Serum enzyme changes in experimental diabetes before and after treatment with some hypoglycaemic drugs.

Authors:  R Awadallah; E A El-Dessoukey
Journal:  Z Ernahrungswiss       Date:  1977-12

6.  Blood glucose, glutathione, and total keto-acids levels in alloxan-diabetic rats.

Authors:  Z El-Hawary; M F El-Hawary; S R Morcus
Journal:  Z Ernahrungswiss       Date:  1977-12

7.  Long-term effects of alloxan in mice.

Authors:  B Ahrén; G Sundkvist
Journal:  Int J Pancreatol       Date:  1995-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.